Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and letrozole in relapsed hormone receptor positive ovarian cancer
NCT02283658Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Mayo Clinic. Started Nov 2014; status: completed.
02
Drugs
everolimus
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02283658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283658.